Active Not Recruiting PHASE1 INTERVENTIONAL 4-arm NCT05828589

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

Sponsor: BeOne Medicines

Conditions Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-cell Lymphoma Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Small Lymphocytic Lymphoma Relapse Diffuse Large B Cell Lymphoma Relapsed Chronic Lymphocytic Leukemia Relapsed Follicular Lymphoma Relapsed Marginal Zone Lymphoma Relapsed Non-Hodgkin Lymphoma Relapsed Small Lymphocytic Lymphoma Richter Transformation Transformed Non-Hodgkin Lymphoma

Interventions BGB-21447

Updated 23 times since 2023 Last updated: Mar 10, 2026 Started: Jun 20, 2023 Primary completion: May 31, 2026 Completion: May 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Refractory Chronic Lymphocytic Leukemia and Refractory Diffuse Large B-cell Lymphoma and is currently ongoing. BeOne Medicines leads this study, which shows 23 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE1
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE1
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE1

▶ Show 18 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Apr 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Apr 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2023 — Aug 2023 [monthly]

Not Yet Recruiting PHASE1
May 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeOne Medicines

Data source: BeOne Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auckland, New Zealand , Baltimore, United States , Beijing, China , Benowa, Australia , Blacktown, Australia , Changzhou, China , Clayton, Australia , Fuzhou, China , Iowa City, United States , Jinan, China and 17 more locations